ProStrakan Group plc
ProStrakan Group plc company specializes in those areas, but also focuses on therapies for women's health and issues relating to the ageing male. ProStrakan's marketed products include brain tumor treatment Bélustine and bone therapy Adcal. Products in development include therapies to treat alopecia and hypogonadism. ProStrakan markets its products to more than 10 countries in the EU, and has applied for FDA approval of pain medication Abstral in the US. ProStrakan company was founded as Strakan in 1995 by Chairman Harry Stratford and changed its name to ProStrakan when it merged with ProSkelia. Warbug Pincus and Aventis Pharma each hold majority shares in the company.
Contact Details
Executives
Chairman
Peter V. Allen
CEO
Wilson Totten